ACTUALITÉS

Inra Transfert est partenaire du Forum Recherche-Industrie 2017 de l’institut Carnot 3BCAR :

Molécules biosourcées : couplages biotechnologies et chimie - 7 mars 2017, Paris

 

Cette journée sera l’occasion pour les entreprises :

-          De rencontrer les chercheurs de 3BCAR lors de rendez-vous BtoB préprogrammés

-          D’assister à des conférences présentant des résultats de recherche et leurs perspectives futures

-          D’être informées des offres technologiques en cours émanant des technologies développées par les laboratoires (en partenariat avec les structures de valorisation et les SATT)

 

L’ensemble de la chaine de valeur sera abordé, de la biomasse jusqu’aux produits fonctionnels, au travers de grandes thématiques :

-          Ressources alternatives pour l’élaboration de molécules biosourcées

-          Lignocelluloses, source de molécules innovantes

-          Biomimétisme, s’inspirer de la nature pour innover

-          Scale-up de procédés : exemples de réussites

-          Fonctionnalisation des lipides pour l’obtention de molécules à haute valeur ajoutée

-          Durabilité des produits biosourcés : mesurer et minimiser les impacts

 

Inscrivez-vous dès maintenant sur la plateforme de l’évènement

 

Tarifs d’inscription :

PME : 80€ H.T.

Autres : 150€ H.T.

-20% pour les adhérents aux pôles de compétitivité sponsor : Pôle IAR, Elastopôle !

 

Pour plus d’informations, contactez :

Alexandre Brosse – alexandre.brosse@inra.fr ou 01 42 75 93 82

 

Bandeau partenaires

 

Les sept propositions de projets – six coordonnées par l’INRA, une par Terres Inovia – dont INRA Transfert à accompagné le dépôt à la deuxième étape du troisième appel du défi sociétal 2 d'Horizon 2020* ont été sélectionnées pour financement.

  • AgriLink coordonnée par Pierre Labarthe, INRA
  • DiverIMPACTS coordonnée par Antoine Messéan, INRA
  • GenTORE coordonnée par Nicolas Friggens, INRA
  • ReMIX coordonnée par Eric Justes, INRA
  • SolACE coordonnée par Philippe Hinsinger, INRA
  • EUCLeg coordonnée par Bernadette Julier, INRA
  • Et la proposition LegVALUE coordonnée par Frédéric Muel, Terres Inovia

 *Horizon 2020 : un programme Européen pour la recherche et l'innovation : pour en savoir plus cliquez ici

Ci-dessous les résumés en anglais de ces projets : 

AgriLink

Agricultural Knowledge: Linking farmers, advisors and researchers to boost innovation

Coordinated by Pierre Labarthe

AgriLink aims to stimulate sustainability transitions in European agriculture through better understanding the roles played by farm advice in farmer decision-making. 

To this end, AgriLink will analyse and improve the role of farmer advice in 8 innovation areas that combine challenges identified in the Strategic Approach to EU Agricultural Research & Innovation. AgriLink builds on the premise that the full range of advice-providing organisations need to be included in the assessment of service provision and innovation adoption.

The methodology combines theoretical insights with cutting edge research methods within a multi-actor, transdisciplinary approach. It draws on ‘micro-AKIS’ (individuals and organisations from whom farmers seek services and exchange knowledge with) analysis in 24 focus regions, sociotechnical scenario development and ‘living laboratories’ where farmers, advisors and researchers work together. Research in focus regions will provide insight in farmers’ micro-AKIS, advisory suppliers’ business models, and regional farm advisory systems. This will feed an assessment of the efficacy of governance of farm-advice-research interactions across Europe. Newly developed advisory methods and new forms of research-practice interaction will be validated and further developed in living laboratories. A socio-technical scenario method will be used to explore, jointly with stakeholders, transition pathways towards more sustainable agriculture.

Crucially, AgriLink builds on insights and experiences from both research and practice. The consortium consists of researchers from different disciplines (institutional economics, innovation studies, AKIS studies, sociology of networks), as well as of advisors (from public, private and farmer-based organisations) from across the EU. Actors from advisory services and AKIS will be active in the validation and dissemination of results, to ensure that all project findings are both scientifically sound and practically useful.

DiverIMPACTS

Diversification through Rotation, Intercropping, Multiple Cropping, Promoted by Actors and Value Chains towards Sustainability

Coordinated by Antoine Messéan

The overall goal of DiverIMPACTS is to realise the full potential of diversification of cropping systems for improved productivity, delivery of ecosystem services and resource-efficient and sustainable value chains by: i) assessing performances of crop diversification through rotation, intercropping and multiple cropping; ii) providing rural areas actors with those key enablers and innovations that would remove existing barriers and ensure actual uptake of benefits of crop diversification at farm, value chain and territory levels; iii) make recommendations to policy-makers to facilitate the coordination of all relevant actors within the value chain. DiverIMPACTS will build on existing experiences of crop diversification by networking and expanding 10 existing field experiments to quantify impacts of crop diversification and by accompanying 25 multi-actor case studies in their dynamic transition. DiverIMPACTS will propose a range of technical and organisational innovations to remove lock-ins from farmers to consumers as well as strategies and recommendations to sustain crop diversification.

The consortium includes a wide range of actors (farmers and farmers’ organisations, advisory services, cooperatives, logistic providers, scientists, industry, representatives of civil society and of rural areas). DiverIMPACTS will, through a multi-actor approach, accompany and support innovation groups in their dynamic process to develop sustainable value chain systems characterised by a high level of crop diversification and new market products. The consortium involves pioneer actors of crop diversification and has great experience in both the design and multi-criteria assessment of innovative systems and the analysis of barriers that may lock-in the transition towards sustainable diversified systems that would contribute to the Rural Renaissance objectives.

EUCLEG

Breeding forage and grain legumes to increase EU’s and China’s protein self-sufficiency

Coordinated by Bernadette Julier

EUCLEG aims to reduce Europe and China’s dependency on protein imports by developing efficient breeding strategies for the legume crops of major economic importance in human food and animal feed. The objective is to improve diversification, crop productivity, yield stability and protein quality of both forage (alfalfa and red clover) and grain (pea, faba bean and soybean) legumes. Using diverse and extensive genetic resources and taking advantage of advanced molecular tools, EUCLEG aims to identify and develop the best genetic resources, phenotyping methods and molecular tools to breed legume varieties with improved performance under biotic and abiotic stresses in the representative European and Chinese agro-ecological areas. The potential for new uses of forage species for human nutrition will be explored. Searchable databases will be developed or built to host passport, agronomic and genetic data facilitating exchanges and use of genetic resources. The evaluation of genetic resources in multi-site trials will give keys to broaden the breeding material and extend agro-ecological adaptation. The genetic architecture of key breeding traits will be analysed using association studies in order to identify molecular markers related to phenotypic traits. Finally, genomic selection strategies will be assessed for their potential to improve genetic progress. Practical tools for genotyping, data management and calculation will be provided to breeders to implement marker-assisted selection and genomic selection leading to the creation of new varieties in the long-term. The partnership gathered in EUCLEG, combining public institutes and private companies of Europe and China, guaranties the transfer of knowledge from research to seed industry.

GenTORE

Genomic management Tools to Optimise Resilience and Efficiency

Coordinated by Nicolas Friggens

The objective of GenTORE is to develop innovative genome-enabled selection and management tools to optimise cattle resilience and efficiency (R&E) in widely varying environments. These tools, incorporating both genetic and non-genetic variables, will be applicable across the full range of systems (beef, milk and mixed), and will thereby increase the economic, environmental and social sustainability of European cattle meat and milk production systems. To achieve this, GenTORE brings together: i) multidisciplinary scientific expertise in genomics, environmental assessment, nutritional physiology, health management, precision livestock farming, mathematical modelling, and socio-economics; ii) partners and stakeholders representing breeding organisations, farm technology companies, farm and veterinary advisory services, and farm sectors (organic, grazing, etc.); iii) a unique data basis including more than 1 million genotypes. This multi-actor team will develop tools for: multi-breed selection for R&E, characterisation of diverse farm environments, large-scale phenotyping of R&E using on-farm technology, on-farm management of breeding and culling decisions, and predicting the consequences for farm resilience of changing breeding and management. These tools are designed to be applicable under commercial conditions at the end of the project. They will allow increased use of the genomic diversity in cattle breeds, e.g. use of selective cross-breeding to best exploit the local production environment. They will also allow farm managers, their advisors, and policy-makers, to assess the relative importance of breeding for animal resilience vs breeding for efficiency, with respect to system resilience. As such GenTORE will not only enable the use of genomic information to facilitate predictive biology of efficiency- and resilience-related traits, but will also increase resilience of livestock production in the face of current and future challenges of climate change and food security.

ReMIX

Redesigning European cropping systems based on species MIXtures

Coordinated by Eric Justes

ReMIX will exploit the benefits of species mixtures to design more diversified and resilient agro-ecological arable cropping systems less dependent on external inputs. Based on a multi-actor approach, ReMIX will produce new knowledge that is both scientifically credible and socially valuable in conventional and organic agriculture. It will tackle practical questions and co-design ready-to-use practical solutions adapted to producing mainly grain cash crops in diverse EU pedo-climatic conditions. ReMIX will: 1) overcome barriers to stimulate the adoption of species mixtures by farmers and in agri-food chains, 2) unravel mechanisms of plant-plant interactions to maximise resource use efficiency, 3) determine the role of species mixtures in controlling diseases, pests and weeds and alleviating yield damages, 4) demonstrate the role of species mixtures in improving ecosystem service provision and development of resilience to biotic stress, 5) identify key traits and create novel breeding and phenotyping methods and tools adapted to species mixtures, 6) generate novel breeding material adapted to grain legume/cereal mixtures, 7) develop generic rules for assembling species for efficient cash crop production using process-based simulation models, 8) develop new management techniques to optimise species mixtures performance, 9) optimise settings and specifications for agricultural machines for harvesting and separating grains, and 10) develop a tool box, an educational serious game and technical booklets for farmers and advisors. The project will span from the specification of end-user needs and the co-design of in-field and on-farm experiments to demonstrations with evaluation of new varieties and practices. ReMIX will contribute to the adoption of productive and resilient agricultural systems based on plants diversity, to increase legume production and competitiveness in EU and to healthier diets based on plant proteins from cereals and legumes.

SolACE

Solutions for improving Agroecosystem and Crop Efficiency for water and nutrient use

Coordinated by Philippe Hinsinger

SolACE's overarching goal is to help European agriculture facing the challenge to deal with more frequent combined limitations of water and nutrients in the coming decades, through the design of novel crop genotypes and agroecosystem management innovations to improve water and nutrient (i.e. N and P) use efficiency. To achieve this goal, SolACE will focus its activities on three major European crops - potato, bread and durum wheat - and will identify the (i) optimum combinations of above- and below-ground traits for improving resource use efficiency, (ii) best-performing genotypes under combined water and N or P stresses and (iii) novel practices that make better use of plant-plant and plant-microbe interactions to access water, N and P resources in conventional, organic and conservation agriculture. SolACE will implement a double interactive innovation loop, based on agroecosystem management and breeding strategies, and will imply the engagement of diverse end-users, across the production chain, from farmers and farm advisors to NGOs, SMEs and larger industries in the agri-business sector, through the SolACE consortium and a range of stakeholders' events. The tested innovations will include crop genotype mixtures, legume-based crop rotations and cover crops, microbial inoculants, as well as improved decision support systems and hybrids or products from genomic selection and participatory evolutionary breeding schemes. SolACE will implement complementary approaches, from data mining, modelling, phenotyping in high throughput platforms and field conditions, to experiments in research stations and farmers' networks in contrasted pedo-climatic zones. Through the co-design and co-assessment with the end-users of the selected novel breeding and management strategies to increase the overall system resource use efficiency, the findings of SolACE will be deemed acceptable and readily available for dissemination to a broad spectrum of stakeholders, including policy-makers.

LEGVALUE

To develop sustainable legume-based farming systems and agri-feed and food chains in the EU

Coordinated by Frédéric Muel, Terres Inovia

The goal of LEGVALUE is to pave the road to develop sustainable and competitive legume-based farming systems and agrifeed and food chains in the EU. To this end, the project will assess both the economic and environmental benefits for the EU agro industry to widely produce and use legumes in a sustainable manner. Using a list of 20 value chains reflecting the market diversity, and a list of 20 farm networks covering the diversity of grain legumes and fodder legumes species, LEGVALUE will demonstrate the added value of various legumes value chains and will provide a range of solutions to improve the economic interest of each actor involved in the value chains to use legumes. The feature of LEGVALUE is an approach to research that takes stakeholder-driven objectives. The gap between research and practice will be overcome with close collaboration between non-academic actors and scientists. LEGVALUE will result in the first decision tool for farmers to choose the optimal legume species with their adapted crop management and to assess the economic and environmental benefits of legumes in the cropping and grassland systems. LEGVALUE will contribute to identifying the supply chains that are the most competitive to foster legumes crops so helping the EU to identify: i) the technological topics that must be supported in priority to enhance legumes development; ii) insights into how to support actors coordination for better added value sharing iii) the new standards that will help trade and process of legumes. LEGVALUE will provide accurate recommendations for the development of legumes in the EU. By removing current market opacity and the design of transition pathways, LEGVALUE will provide scientific support for EU and national policy-makers directed at increasing legume production, support technological innovation and organisational innovation in supply chains, meeting the EU Parliament 2011 motion on increasing self-sufficiency on protein rich plant materials.

logo inraTransfert final HD 01Le rapport annuel 2015 d'INRA Transfert est disponible.

Cliquez sur le lien ci-dessous pour le consulter.

 Rapport-dActivit-INRA-Transfert-2015.pdf

 

MaaT Pharma

MaaT Pharma announces €10 million fundraising and pursues the development of the first worldwide autologous microbiotherapy solution

The investment transaction, led by CM-CIC Innovation with Seventure Partners, the pharmaceutical firm Biocodex and the Inra, will allow the start-up to enter the clinical phase. MaaT Pharma is developing a medicine providing treatment for dysbiosis following major treatment against cancer and certain infections

 

20160322 121605

Lyon, March 22, 2016 – MaaT Pharma, a reference for the microbiome industry, is announcing a significant €10 million fundraising operation within the context of its series A. This will notably allow the company to finance the launch of its clinical studies, to begin this summer, with the objective of developing an innovative medicine for correcting dysbiosis following the treatment of diseases such as leukaemia or bone and joint infections. These developments will also allow research to progress in the field of the human microbiome, an area in which France is at the cutting edge and which opens up new prospects regarding the prevention and treatment of several chronic and infectious diseases.
 
The transaction brings together scientific, industrial and financial players: Seventure Partners and the Inra, MaaT Pharma’s historic partners, joined today by CM-CIC Innovation, leader for this second round and the pharmaceutical company Biocodex, which specialises in the therapeutic domains of gastroenterology, neuropsychiatry and pain treatment. This significant investment bears witness to the scientific, therapeutic and economic potential of research on the microbiome.
 
“This fundraising transaction confirms the relevance of our autologous approach, which distinguishes MaaT Pharma from its competitors. It also rewards the quality and rigour of the work carried out. I would like to thank the team for its commitment, as well as our investors for their faith in us. We are very proud that we will be able to strengthen our relations in this way with our historic partners and initiate a collaboration with new investors,” commented Hervé Affagard, CEO of MaaT Pharma.

Laureate of the Worldwide Innovation Challenge (phase 2)[1] and being part of the 10 finalists of the international start-ups acceleration program Big Booster[2], MaaT Pharma is developing the first safe and standardised autologous microbiotherapy solution, in conformity with the good clinical pharmaceutical practice. This solution will allow to treat dysbiosis in hospitalised patients in a specific and individualised manner. The imbalances of the microbiome following certain extensive treatments have the notable consequence of the emergence of opportunistic infections, such as Clostridium difficile or Multi-Drug Resistant Bacteria. These are the most frequent causes of diarrhea following a hospital stay. In the medium term, the autologous microbiotherapy platform developed by MaaT Pharma will permit the extension of its range of products for other therapeutic areas, for example blood cancers.
This €10 million fundraising operation is in line with MaaT Pharma’s initial development plan and will be accompanied by new hirings in forthcoming months.
 
“We found MaaT Pharma’s way of thinking particularly seducing, as it combines an autologous approach with an industrial, quantifiable and reproducible process, therefore in line with the medical world’s hopes and the patients’ needs. The Inra’s partnership was also a key element for us, as it is very smooth and efficient. We are thrilled to be able to work along such a talented team and to help promote a new therapeutic approach,” added Karine Lignel, Deputy CEO of CM-CIC Innovation.
 
“This Series A financing round confirms Seventure’s initial decision to support MaaT Pharma from its inception. As the European leader in microbiome-related investment, and thanks to the Health for Life fund, first fund focused on the microbiome, Seventure has the means to support MaaT Pharma, as well as numerous other innovators in this field, towards creation of treatments for patients in need.  If MaaT Pharma’s initial studies are successful, this will open possibilities for many more products, in indications ranging from inflammation to cancer,” said Isabelle de Crémoux, CEO of Seventure Partners.

“Drawing on its expertise in the field of intestinal microbiota, Biocodex is delighted to support the development of MaaT Pharma in its innovative and original project to correct dysbiosis. This cooperation aims to provide new therapeutic solutions via the autologous transplantation of intestinal microbiota in the event of illnesses or treatments which have seriously altered it,” indicated Jean-Marie LEFEVRE, CEO of Biocodex.
 
"We are delighted with our partnership with Maat Pharma and with this fundraising which confirms the legitimacy of the autologous approach. Our goal is to accelerate the development of the inventions of Inra laboratories with our industrial partners. Maat Pharma will be able to implement at the patient's level the scientific approaches developed within the Micalis and MetaGenoPolis units in a scientific field at the heart of the strategic priorities of innovation of Inra" comments Rejane Le Tinévez, Executive director of Inra Transfert.


MaaT Pharma’s ambition: to embody a new medical paradigm
Since its creation at the end of 2014, MaaT Pharma has undergone exponential development. After a first fundraising round of €2 million, carried out in December 2014, MaaT Pharma has already validated the safety and the dose of its drug candidate, during pre-clinical trials carried out in 2015 in partnership with the Inra. The start-up has also just completed the prototyping of a unique solution, allowing the collection of the sampled microbiome and guaranteeing the safety of all of the players (patient, operator, medical staff) until the administration phase.
MaaT Pharma has set itself the objective of being a player in the emergence of a new medical paradigm around the role played by the intestinal microbiome in health and well-being. Its priority action lines relate to the correction of dysbiosis and associated complications, the eradication of Multi-Drug Resistant Bacteria, the prevention of nosocomial diseases, the re-establishment of key functions of the intestinal microbiome and the stimulation of the immune system and restoration of metabolic functions.


About MaaT Pharma
MaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and Bone & Joint Infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.

 

For more information: www.maatpharma.com
Follow us on Twitter: @MaaT_Pharma
Follow us on LinkedIn: http://www.linkedin.com/company/maat-pharma

 

Key dates of MaaT Pharma
December 2014: creation
July 2015: €2 million fundraising
September 2015: winner of the International Innovation Awards
November 2015: validation of the pre-clinical phase of its autologous microbiotherapy solution
February 2016: selected for the TOP10 Big Booster (final in April 2016)
March 2016: €10 million fundraising


 

CM CIC

About

CM-CIC Innovation is a subsidiary of CM-CIC Investissement, the Crédit Mutuel - CIC group's investment and merchant bank division. With more than 2.6 billion Euros worth of equity under management and over 600 portfolio companies, CM-CIC Investissement is a key player in capital investment in France, backed by its own equity resources.
CM-CIC Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, information technology, industrial innovations or environment.

For more details: www.cmcic-¬investissement.com


 

 Seventure

About

With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, especially fintech & assurtech, in France and Germany, and in the life sciences field across Europe and North America. In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.
Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.

For more details: www.seventure.com


 

Biocodex

About

Biocodex is an independent family-owned pharmaceutical company, founded in Paris, France in 1953. The company initially concentrated on gastroenterology and specifically on the discovery of a promising probiotic substance, Saccharomyces boulardii (sold under the ULTRA-LEVURE brand in France). Biocodex has maintained partnerships with health sector professionals for 60 years, with the mission of developing intelligent solutions that respond to contemporary healthcare issues. Biocodex has become a multinational research and development, manufacturing and marketing company. The company is currently active in over 100 countries, with subsidiaries in Belgium, Russia, Ukraine, Turkey, Morocco, Mexico, the United States and through partnerships with distributors. Today, Biocodex specialises at international level in the therapeutic domains of gastroenterology, neuropsychiatry and pain treatment.

For more details: www.biocodex.fr/en/


 

logo

About

A subsidiary of the Institut National de Recherche Agronomique [National Institute of Agricultural Research], Inra Transfert is a project engineering and technology transfer company for innovation in food, agriculture and the environment.
In its role of providing a link between research and society, Inra Transfert carries out five major missions:

Transferring research results to companies by developing and managing its portfolio of technologies via operating agreements with industrialists;
Promoting the creation of innovative companies by supporting their development;
Support in setting up, negotiating and steering European or national collaborative research projects by virtue of its expertise in engineering management projects;

Designing, promoting and managing major research and development programmes,
Providing resources to the eco-technology sector by creating a fluid interface between public research laboratories and the financial world.

For more details: www.inra-transfert.fr/en/


Press Contact:
Xavier Cayon
Agence Ekno
+33 6 23 12 63 46
xavier.cayon@ekno.fr 
________________________________________
[1] http://www.entreprises.gouv.fr/innovation-2030/home-innovation-2030?language=en-gb
[2] www.bigbooster.org